Skip to main content
. Author manuscript; available in PMC: 2021 Oct 21.
Published in final edited form as: Nat Med. 2020 Oct 26;26(12):1852–1858. doi: 10.1038/s41591-020-1089-8

Fig. 1 ∣. Overview of the Beat AML trial.

Fig. 1 ∣

a, AML prioritization by genomic or cytogenetic abnormality into groups. b, Patient distribution following enrollment on the Beat AML trial. c, Genomic assignment of eligible patients with AML by prioritization group. The asterisk denotes the hypermethylation group, which is defined by the TET2/WT1 mutations.